SecBot SecBot
PRESS-RELEASE ·Filed Jun 5, 2026

TEVA

Teva Pharmaceutical Industries Ltd
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The data is clinically supportive but does not change Teva's near-term financial outlook. Monitor for any future label expansion or competitive dynamics in the HD chorea market, but no immediate trading catalyst from this release.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.19
T+0 close · Jun 5, 2026 · via day close
Latest settled
+5.43%
T+60 · $36.05
Vs SPY
+1.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $34.19entry
  2. T+1 · 5mo ago −2.72%α −2.95% · $33.26
  3. T+5 · 5mo ago +1.29%α +0.72% · $34.63
  4. T+20 · 4mo ago +3.22%α +1.36% · $35.29
  5. T+60 · 3mo ago +5.43%α +1.43% · $36.05

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's disease chorea led to patient-reported improvements in movement and quality of life, with 74% of patients reporting improvement and over 85% reporting better daily activities and social life. The data reinforces the drug's clinical value but does not provide new financial figures, regulatory decisions, or guidance changes.

Key Facts

  • Data from a real-world, decentralized study on HD chorea patients treated with AUSTEDO/AUSTEDO XR presented at the Advanced Therapeutics in Movement & Related Disorders Congress (June 4-8, 2026).
  • 74% of patients reported improvement in chorea movements since initiating treatment (PGIC scale).
  • Over 85% of patients reported improvements in goals related to daily activities and social life.
  • 77% of caregivers reported improvements in goals related to their social life and emotional wellbeing.
  • No new financial data, revenue, EPS, guidance, or regulatory action was disclosed in the press release.

Financial Impact

No financial figures provided; the press release is a clinical data update without revenue or earnings implications.

Risk Factors

  • No new revenue or earnings data; the press release is purely clinical and does not alter financial expectations.
  • Forward-looking statements about AUSTEDO commercialization are subject to competitive and regulatory risks.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3307494

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026